Tiotropium In Exercise
Public ClinicalTrials.gov record NCT00525512. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.
Study identification
- NCT ID
- NCT00525512
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 519 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2007
- Primary completion
- May 31, 2010
- Completion
- Not listed
- Last update posted
- Dec 23, 2013
Started 2007
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.368.01023 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 205.368.01022 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 205.368.01003 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 205.368.01008 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 205.368.01017 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 205.368.01028 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 205.368.01004 Boehringer Ingelheim Investigational Site | Bay Pines | Florida | — | — |
| 205.368.01013 Boehringer Ingelheim Investigational Site | North Miami Beach | Florida | — | — |
| 205.368.01025 Boehringer Ingelheim Investigational Site | Hazard | Kentucky | — | — |
| 205.368.01029 Boehringer Ingelheim Investigational Site | Biddeford | Maine | — | — |
| 205.368.01016 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 205.368.01002 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 205.368.01021 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 205.368.01014 Boehringer Ingelheim Investigational Site | Albany | New York | — | — |
| 205.368.01030 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 205.368.01018 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.368.01027 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 205.368.01019 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 205.368.01020 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 205.368.01024 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 205.368.01015 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
Recently updated Pulmonary Disease, Chronic Obstructive trials
Other public records listing Pulmonary Disease, Chronic Obstructive. Sorted by last update posted; newest first. Not a recommendation.
- NCT07759245: A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Not yet recruiting
- NCT07177339: eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Recruiting
- NCT07714252: Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD Not yet recruiting
- NCT05718102: Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD Active, not recruiting
- NCT04669743: Innate Immunity in Ozone-induced Airway Inflammation in COPD Active, not recruiting
- NCT06961214: Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00525512, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 23, 2013 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00525512 live on ClinicalTrials.gov.